AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06463587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cladribine High Dose
Description: Participants will receive a total of cladribine high dose in two courses separated by 4 weeks.
Study NCT06548360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Study NCT06548360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study NCT05781061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for Eligibility
Description: Asynchronous Screening for MA Eligibility
Study NCT06044311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: 200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
Study NCT06044311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Neoadjuvant chemotherapy treatment as per standard of care.
Study NCT06044311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Radiation
Description: Neoadjuvant radiation treatment as per standard of care.
Study NCT06251973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AgenT-797
Description: AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors
Study NCT06251973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody
Study NCT06251973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Botensilimab is supplied as a sterile, single-use solution for IV administration
Study NCT06251973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
Study NCT06251973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
Study NCT05601700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: ATC: L02BG04
Study NCT05601700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin AUC 5 and paclitaxel 175 mg/m2
Description: ATC: L01XA02 and ATC: L01CD01 respectively
Study NCT05614739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral
Study NCT05614739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV
Study NCT05365061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periosteal electrical dry needling with no maintenance treatments
Description: periosteal electrical dry needling
Study NCT05365061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periosteal electrical dry needling with maintenance treatments every other month
Description: periosteal electrical dry needling with maintenance treatments every other month
Study NCT05365061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periosteal electrical dry needling with monthly maintenance treatments
Description: periosteal electrical dry needling with monthly maintenance treatments
Study NCT05538065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up booster Alert
Description: Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
Study NCT05538065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-commitment
Description: A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
Study NCT05538065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Alert
Description: An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: 50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-Transplant Cyclophosphamide
Description: 50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycophosphamide
Description: Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymoglobulin
Description: Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymoglobulin
Description: Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: 2 grays on Day-1 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cells
Description: High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
Study NCT06252870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hematopoietic stem cells
Description: High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
Study NCT06252870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graft nuclear cells
Description: Graft nuclear cells CD3+ cells if needed after transplantation
Study NCT06252870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graft nuclear cells
Description: Graft nuclear cells CD3+ cells if needed after transplantation
Study NCT06252870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Lymphocytes Injection
Description: DLI with CD3+ if relapse after transplantation or in prevention of relapse
Study NCT06252870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocytes Injection
Description: DLI with CD3+ if relapse after transplantation or in prevention of relapse
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
Study NCT06252870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
Study NCT05792085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-based GDMT Optimization
Description: Patients will be prescribed appropriate GDMT for HFrEF if they meet clinical criteria by the study team, appropriate lab work and follow up testing will be sent and followed up by the team. All recommendations and plans will be copied to primary care providers who can opt out if disagree, but also to improve telementoring to build clinical comfort.
Study NCT06090305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: levidex
Description: Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
Study NCT06090305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
Study NCT06090305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: treatment as usual (TAU)
Study NCT06090305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: treatment as usual (TAU)
Study NCT06015490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus: Sucrose (aim 1)
Description: Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06015490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus: Glucose (aim 1)
Description: Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06015490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus: Fructose (aim 1)
Description: Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06015490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus: Sucrose (aim 2)
Description: Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06015490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus: High Fructose Corn Syrup (aim 2)
Description: Participants will consume flavored beverage solutions containing 110 calories of high fructose corn syrup in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06015490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)
Description: Participants will consume flavored beverage solutions containing a non-nutritive sweetener and 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06506448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Coronary Angiography
Description: CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
Study NCT06344481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical (Hyalex Cartilage Knee Implant)
Description: Implantation of Hyalex Cartilage Knee Implant.
Study NCT05742906 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve
Description: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
Study NCT06314724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: lyophilized powder,subcutaneous injection
Study NCT06314724 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: lyophilized powder,subcutaneous injection
Study NCT05125679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered by subcutaneous injection.
Study NCT06648824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Oral tablets
Study NCT06648824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup
Study NCT05695261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial Transplantation Therapy
Description: Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
Study NCT05695261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
Study NCT05695261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (in place of MTT)
Description: Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
Study NCT05718557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYX-106
Description: Intravenous (IV) infusion
Study NCT05299658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNMAu8
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
Study NCT05219396 — intervention group
Intervention type: DEVICE
Intervention: Knee arthroplasty
Description: Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
Study NCT05819346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after rehabilitation or treatment has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
Study NCT06217393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride Hydrochloride 150 mg extended release tablets
Description: The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
Study NCT06217393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride Hydrochloride 50 mg film coated tablets
Description: The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
Study NCT04646096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAKO THA 4.0 System
Description: Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery.
Study NCT06101056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Junior Enlisted Component
Description: Junior Enlisted Airmen (E4 and below) will complete 10 online modules designed to train them on recognizing SH and SA, healthy and unhealthy relationships, and situations that may increase risk for SH and SA. Participants will adopt and practice a lifestyle paradigm of select-detect-protect, in which service members select their personal rule to have only healthy (non-abusive) relationships with their peers and romantic partners, detect signs and situations that might threaten their rules, and protect their rules using communication, management, and avoidance skills. They will be instructed to adopt a zero-tolerance approach to SH and SA and will receive skills training related to communication and conflict resolution for healthy relationships, reduction of SH and SA perpetration, consent communication, reporting incidents of SH and SA, and bystander intervention. Participants who have experienced SH or SA are encouraged to use the Get Help Now feature to access support 24/7.
Study NCT06101056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Component
Description: Mid- and advanced-level leaders (E5 and above) will complete 10 online modules designed to train them to recognize forms of SH and SA, how to respond to an incident of SH or SA, and how to create a safe work environment free of SH and SA. Leaders will also adopt and practice the paradigm select-detect-protect. Leaders will select their personal rule to enforce a healthy work environment (free of SH and SA), detect signs and situations that might threaten their rule (e.g., displaying inappropriate pictures on the computer), and protect their rules using communication and management skills. Leaders will also be given background material on SH and SA in the military (e.g., extent of the problem, DoD definitions, and policies) and installation resources for reporting incidents. As with the Junior Enlisted component, Leaders who may have experienced SH or SA are encouraged to use our Get Help Now feature to access support 24/7.